This activity is expired and is no longer available for CME credit.


On the Scenes at EULAR: Updates on Current and Emerging Therapies

Author(s)/Faculty: Philip G. Conaghan, MBBS, PhD, FRACP, FRCP; Tom W. J. Huizinga, MD, PhD
Release Date: 8/5/2015Expiration Date: 8/4/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Clinicians have several classes of highly effective biologic and conventional disease modifying antirheumatic agents (DMARDs) used for the treatment of rheumatoid arthritis (RA) in their armamentarium. However, despite this, some patients do not receive early, aggressive treatment. Conversely, others may be placed aggressive therapy but continue to live with high disease activity due to a lack of response to their medication, toxicity, or a loss of medication efficacy. In these interviews, Drs. Huizinga and Conaghan discuss promising results from clinical trials of current and emerging biologic and small molecule DMARDs that may expand therapeutic options.